As global markets experience a positive shift with signs of de-escalation in the Middle East and strong earnings reports, investor sentiment is buoyed across major indices. In this context, penny stocks—often representing smaller or less-established companies—remain an intriguing investment area due to their potential for significant value growth. While the term may seem outdated, these stocks can offer opportunities for growth when backed by solid financials and a clear trajectory, making them worth watching for those interested in exploring under-the-radar investments.
Top 10 Penny Stocks In Asia
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| Guoquan Food (Shanghai) (SEHK:2517) |
HK$3.14 |
HK$8.26B |
★★★★★★ |
| Lever Style (SEHK:1346) |
HK$1.47 |
HK$911.18M |
★★★★★★ |
| Natural Food International Holding (SEHK:1837) |
HK$1.71 |
HK$3.74B |
★★★★★★ |
| North East Rubber (SET:NER) |
THB4.90 |
THB9.05B |
★★★★☆☆ |
| YesAsia Holdings (SEHK:2209) |
HK$3.22 |
HK$1.35B |
★★★★★☆ |
| PC Partner Group (SGX:PCT) |
SGD1.82 |
SGD705.95M |
★★★★★★ |
| CNMC Goldmine Holdings (Catalist:5TP) |
SGD1.44 |
SGD583.62M |
★★★★★★ |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) |
SGD4.18 |
SGD16.45B |
★★★★★☆ |
| Bosideng International Holdings (SEHK:3998) |
HK$4.30 |
HK$49.97B |
★★★★★★ |
| Scott Technology (NZSE:SCT) |
NZ$2.40 |
NZ$201.83M |
★★★★★☆ |
Click here to see the full list of 933 stocks from our Asian Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Cosmo Lady (China) Holdings
Simply Wall St Financial Health Rating:★★★★★★
Overview:Cosmo Lady (China) Holdings Company Limited is an investment holding company involved in the design, research, development, and sale of branded intimate wear products in China with a market cap of HK$948.02 million.
Operations:Cosmo Lady (China) Holdings does not report specific revenue segments.
Market Cap:HK$948.02M
Cosmo Lady (China) Holdings, with a market cap of HK$948.02 million, recently announced a dividend increase to 1.6 Hong Kong cents per share for 2025, reflecting its commitment to shareholder returns. Despite a slight decline in sales and net income compared to the previous year, the company maintains strong financial health, with short-term assets exceeding both short-term and long-term liabilities. Its price-to-earnings ratio of 6.7x suggests it is undervalued relative to the Hong Kong market average. The management team and board are experienced, contributing positively to governance stability amidst an unstable dividend track record.
Tian An China Investments
Simply Wall St Financial Health Rating:★★★★★★
Overview:Tian An China Investments Company Limited is an investment holding company that focuses on investing in, developing, and managing properties in the People's Republic of China, Hong Kong, and the United Kingdom with a market cap of HK$6.54 billion.
Operations:The company's revenue is primarily derived from Property Development at HK$7.78 billion, followed by Healthcare at HK$1.58 billion, Property Investment at HK$574.38 million, and Other Operations at HK$560.19 million.
Market Cap:HK$6.54B
Tian An China Investments has experienced a significant turnaround, reporting HK$10.5 billion in sales and HK$1.77 billion net income for 2025, compared to a loss the previous year. This improvement is largely due to revenue from The One Tian An Place project in Shanghai. The company declared an increased interim dividend of HKD 20 cents per share, indicating confidence in its financial health. With short-term assets exceeding liabilities and reduced debt levels, Tian An demonstrates solid balance sheet management. Its seasoned management and board enhance governance stability amid its volatile earnings history as a penny stock investment option.
Sichuan Hebang Biotechnology
Simply Wall St Financial Health Rating:★★★★☆☆
Overview:Sichuan Hebang Biotechnology Corporation Limited is involved in the production of agricultural, chemical, and new material products with a market cap of CN¥24.16 billion.
Operations:Sichuan Hebang Biotechnology Corporation Limited has not reported specific revenue segments.
Market Cap:CN¥24.16B
Sichuan Hebang Biotechnology has shown a mixed financial performance, with a recent report indicating sales of CN¥1.39 billion for Q1 2026, down from CN¥1.73 billion the previous year. Despite this decline in sales, net income rose significantly to CN¥173.59 million from CN¥12.52 million, suggesting improved operational efficiency or cost management. The company's short-term assets comfortably cover both short and long-term liabilities, reflecting strong liquidity management despite increasing debt levels over five years. However, its unprofitability and high share price volatility present challenges for investors considering it as a penny stock opportunity in Asia's market landscape.
Make It Happen
-
Unlock more gems! Our Asian Penny Stocks screener has unearthed 930 more companies for you to explore.Click here to unveil our expertly curated list of 933 Asian Penny Stocks .
-
Interested In Other Possibilities? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2298 SEHK:28 and SHSE:603077.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
